108 related articles for article (PubMed ID: 19808962)
1. Differences in tumor regulatory T-cell localization and activation status impact patient outcome.
Ménétrier-Caux C; Gobert M; Caux C
Cancer Res; 2009 Oct; 69(20):7895-8. PubMed ID: 19808962
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Gobert M; Treilleux I; Bendriss-Vermare N; Bachelot T; Goddard-Leon S; Arfi V; Biota C; Doffin AC; Durand I; Olive D; Perez S; Pasqual N; Faure C; Ray-Coquard I; Puisieux A; Caux C; Blay JY; Ménétrier-Caux C
Cancer Res; 2009 Mar; 69(5):2000-9. PubMed ID: 19244125
[TBL] [Abstract][Full Text] [Related]
3. Increase of regulatory T cells in the peripheral blood of dogs with metastatic tumors.
Horiuchi Y; Tominaga M; Ichikawa M; Yamashita M; Jikumaru Y; Nariai Y; Nakajima Y; Kuwabara M; Yukawa M
Microbiol Immunol; 2009 Aug; 53(8):468-74. PubMed ID: 19659931
[TBL] [Abstract][Full Text] [Related]
4. Polyps wrap mast cells and Treg within tumorigenic tentacles.
Colombo MP; Piconese S
Cancer Res; 2009 Jul; 69(14):5619-22. PubMed ID: 19567669
[TBL] [Abstract][Full Text] [Related]
5. Emerging strategies in regulatory T-cell immunotherapies.
Gajewski TF; Chesney J; Curriel TJ
Clin Adv Hematol Oncol; 2009 Jan; 7(1):1-10; quiz 11-2. PubMed ID: 19288606
[TBL] [Abstract][Full Text] [Related]
6. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
7. Treg(s) in Cancer: Friends or Foe?
Wolf D; Sopper S; Pircher A; Gastl G; Wolf AM
J Cell Physiol; 2015 Nov; 230(11):2598-605. PubMed ID: 25913194
[TBL] [Abstract][Full Text] [Related]
8. Levels of dendritic cell populations and regulatory T cells vary significantly between two commonly used mouse strains.
Vogelsang P; Hovden AO; Jonsson R; Appel S
Scand J Immunol; 2009 Dec; 70(6):541-6. PubMed ID: 19906196
[TBL] [Abstract][Full Text] [Related]
9. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.
Attig S; Hennenlotter J; Pawelec G; Klein G; Koch SD; Pircher H; Feyerabend S; Wernet D; Stenzl A; Rammensee HG; Gouttefangeas C
Cancer Res; 2009 Nov; 69(21):8412-9. PubMed ID: 19843860
[TBL] [Abstract][Full Text] [Related]
11. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
[TBL] [Abstract][Full Text] [Related]
12. Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers.
Mann DL; Celluzzi CM; Hankey KG; Harris KM; Watanabe R; Hasumi K
Ann N Y Acad Sci; 2009 Sep; 1174():41-50. PubMed ID: 19769735
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation.
Pierau M; Engelmann S; Reinhold D; Lapp T; Schraven B; Bommhardt UH
J Immunol; 2009 Nov; 183(10):6124-34. PubMed ID: 19841181
[TBL] [Abstract][Full Text] [Related]
14. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
Radfar S; Wang Y; Khong HT
J Immunol; 2009 Nov; 183(10):6800-7. PubMed ID: 19846868
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the prognostic value of regulatory T cells in patients with cancer.
Badoual C; Hans S; Fridman WH; Brasnu D; Erdman S; Tartour E
J Clin Oncol; 2009 Jul; 27(19):e5-6; author reply e7. PubMed ID: 19470910
[No Abstract] [Full Text] [Related]
16. Nonfunctional regulatory T cells and defective control of Th2 cytokine production in natural scurfy mutant mice.
Lahl K; Mayer CT; Bopp T; Huehn J; Loddenkemper C; Eberl G; Wirnsberger G; Dornmair K; Geffers R; Schmitt E; Buer J; Sparwasser T
J Immunol; 2009 Nov; 183(9):5662-72. PubMed ID: 19812199
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T-cells in periapical lesions.
Colić M; Gazivoda D; Vucević D; Majstorović I; Vasilijić S; Rudolf R; Brkić Z; Milosavljević P
J Dent Res; 2009 Nov; 88(11):997-1002. PubMed ID: 19828886
[TBL] [Abstract][Full Text] [Related]
18. Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors.
Whiteside TL; Miescher S; Moretta L; von Fliedner V
Transplant Proc; 1988 Apr; 20(2):342-3. PubMed ID: 3363635
[No Abstract] [Full Text] [Related]
19. Thymic regulation of autoimmune disease by accelerated differentiation of Foxp3+ regulatory T cells through IL-7 signaling pathway.
Chen X; Fang L; Song S; Guo TB; Liu A; Zhang JZ
J Immunol; 2009 Nov; 183(10):6135-44. PubMed ID: 19841165
[TBL] [Abstract][Full Text] [Related]
20. Conversion of peripheral CD4(+)CD25(-) T cells to CD4(+)CD25(+) regulatory T cells by IFN-gamma in patients with Guillain-Barré syndrome.
Huang S; Li L; Liang S; Wang W
J Neuroimmunol; 2009 Dec; 217(1-2):80-4. PubMed ID: 19853929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
